chemotherapy for patients with MC versus those with AC

Slides:

Advertisements

Similar presentations

Figure #1 Overall survival Figure #2 Disease free survival

Advertisements

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Management of personal care needs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Evidence Behind the 4-Hour Rule for Initiation of Antibiotic Therapy in Community- Acquired Pneumonia Kenneth T. Yu, MD, MBA, Peter C. Wyer, MD Annals.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Figure 3 Care needs of patients with advanced-stage cancer

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Clinical vignette and putative causal relationships

Figure 5 Palliative-care-referral patterns

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Frequency and overlap of alterations

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

David J.A. Jenkins et al. JACC 2018;71:

Renal Replacement Therapy in Acute Kidney Injury

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Figure 3 Determination of the primary site

Zachary L. Steinberg et al. JACC 2017;69:

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Figure 1 Gene-expression quantification methods

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

chemotherapy for patients with MC versus those with AC Figure 1 Forrest plot depicting outcomes from studies of palliative and adjuvant chemotherapy for patients with MC versus those with AC Figure 1 | Forrest plot depicting outcomes from studies of palliative and adjuvant chemotherapy for patients with MC versus those with AC. Differences between categorical outcomes were calculated by the author based on primary data reported in the relevant manuscript using the risk ratio and corresponding 95% CI. Abbreviations: AC, adenocarcinoma not otherwise specified; CI, confidence interval; MC, mucinous carcinoma. Hugen, N. et al. (2015) Advances in the care of patients with mucinous colorectal cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.140